Jeffrey Bacha of Del Mar Pharmaceuticals Inc. (DMPI) speaks with Equities.com at the Small-Cap Stars Spring Conference 2015. DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.
Here is the presentation he did at the conference.
This video interview may include forward-looking statements that involve risks and uncertainties. Forward- looking statements are statements that are not historical facts and are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. To read our full disclosure, please go to: http://www.equities.com/disclaimer.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer